SHIFT AI Newsroom · UK
MHRA Warns of Potential Risk of Pulmonary Aspiration with GLP-1 and Dual GIP/GLP-1 Receptor Agonists
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the potential risk of pulmonary aspiration during general anaesthesia or deep sedation with GLP-1 and dual GIP/GLP-1 receptor agonists
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update regarding the potential risk of pulmonary aspiration during general anaesthesia or deep sedation with GLP-1 and dual GIP/GLP-1 receptor agonists. This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines.
What this means in the UK
This update is relevant to UK patients and healthcare professionals who use or prescribe GLP-1 and dual GIP/GLP-1 receptor agonists, as it highlights a potential risk associated with their use during general anaesthesia or deep sedation
Known facts
- The MHRA has issued a drug safety update regarding the potential risk of pulmonary aspiration with GLP-1 and dual GIP/GLP-1 receptor agonists